Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$47.98 - $54.4 $198,109 - $224,617
4,129 New
4,129 $223,000
Q3 2023

Feb 16, 2024

BUY
$57.89 - $64.73 $239,027 - $267,270
4,129 New
4,129 $239,000
Q3 2023

Oct 31, 2023

SELL
$57.89 - $64.73 $86,545 - $96,771
-1,495 Reduced 26.58%
4,129 $239,000
Q2 2023

Feb 16, 2024

BUY
$63.71 - $70.74 $358,305 - $397,841
5,624 New
5,624 $359,000
Q1 2023

Apr 28, 2023

BUY
$65.71 - $74.53 $156,324 - $177,306
2,379 Added 73.31%
5,624 $389,000
Q4 2022

Feb 02, 2023

SELL
$68.48 - $81.09 $38,348 - $45,410
-560 Reduced 14.72%
3,245 $233,000
Q1 2022

May 02, 2022

BUY
$61.48 - $73.72 $3,688 - $4,423
60 Added 1.6%
3,805 $278,000
Q1 2021

May 07, 2021

SELL
$59.34 - $66.74 $4,272 - $4,805
-72 Reduced 1.89%
3,745 $236,000
Q4 2020

Feb 09, 2021

SELL
$57.74 - $65.43 $27,946 - $31,668
-484 Reduced 11.25%
3,817 $237,000
Q3 2020

Nov 09, 2020

SELL
$57.43 - $63.64 $1.81 Million - $2.01 Million
-31,594 Reduced 88.02%
4,301 $259,000
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $971,629 - $1.14 Million
17,724 Added 97.54%
35,895 $2.11 Million
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $642,500 - $933,703
13,847 Added 320.24%
18,171 $1.01 Million
Q4 2019

Feb 03, 2020

BUY
$49.21 - $64.19 $212,784 - $277,557
4,324 New
4,324 $277,000
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $184,069 - $238,693
-3,775 Closed
0 $0
Q3 2018

Oct 15, 2018

SELL
$55.19 - $62.25 $14,901 - $16,807
-270 Reduced 6.67%
3,775 $234,000
Q2 2018

Jul 30, 2018

BUY
$50.53 - $62.98 $6,821 - $8,502
135 Added 3.45%
4,045 $224,000
Q1 2018

Apr 23, 2018

SELL
$59.92 - $68.98 $33,315 - $38,352
-556 Reduced 12.45%
3,910 $247,000
Q4 2017

Feb 15, 2018

BUY
$59.94 - $65.35 $267,692 - $291,853
4,466
4,466 $274,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Main Street Investment Advisors LLC Portfolio

Follow Main Street Investment Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Main Street Investment Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Main Street Investment Advisors LLC with notifications on news.